Literature DB >> 3911375

Emergence of beta-lactam multiresistant variants of gram-negative bacilli in the presence of cefotaxime.

P L Svarva, R V Lyng, J A Maeland.   

Abstract

88 clinical isolates of gram-negative bacilli (23 Enterobacter, 23 Klebsiella, 21 E. coli, and 21 Pseudomonas) all showed susceptibility to one or more cephalosporins and were nitrocefin test negative. When cultured overnight in the presence of 1, 10, or 100 mg/l of cefotaxime, 19 Enterobacter strains grew beta-lactamase-producing variants, 15 of them at concentrations less than or equal to 10 mg/l of cefotaxime. All enzyme-producing variants showed resistance to a number of cephalosporins including non-hydrolyzable cephalosporins and other beta-lactam antibiotics, except mecillinam and thienamycin. With the other gram-negative bacilli resistant mutants did not emerge in the presence of cefotaxime. These findings are discussed in relation to use of third generation cephalosporins as first hand monotherapy in patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3911375     DOI: 10.3109/13813458509058779

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia.

Authors:  W C Tsai; R M Strieter; B Mehrad; M W Newstead; X Zeng; T J Standiford
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia.

Authors:  L L Laichalk; K A Bucknell; G B Huffnagle; J M Wilkowski; T A Moore; R J Romanelli; T J Standiford
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia.

Authors:  L L Laichalk; S L Kunkel; R M Strieter; J M Danforth; M B Bailie; T J Standiford
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.